SCHEDULE: Atlas Venture Funds Disclose Obsidian Therapeutics Stake

Multiple Atlas Venture funds have collectively reported beneficial ownership of 7.3% of Obsidian Therapeutics, Inc. common stock as of August 3, 2026.

Summary

• This filing is a Schedule 13G, indicating a change in beneficial ownership of Obsidian Therapeutics, Inc. common stock.
• Several Atlas Venture entities, including Atlas Venture Fund X, L.P., Atlas Venture Opportunity Fund I, L.P., Atlas Venture Opportunity Fund II, L.P., and Atlas Venture Opportunity Fund III, L.P., along with their respective general partners, are reporting their holdings.
• Collectively, these entities beneficially own 4,503,149 shares of common stock, representing 7.3% of the issuer's outstanding shares.
• The reporting date for this event is August 3, 2026.
• The filing includes a joint filing agreement among the reporting persons.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine Schedule 13G filing disclosing beneficial ownership changes rather than providing operational or financial performance updates.

Positives

• Disclosure of significant investment by a prominent venture capital firm (Atlas Venture) can signal confidence in the company's long-term prospects.
• The collective ownership of 7.3% indicates a substantial stake, potentially aligning the investor's interests with other shareholders.

Negatives

• The filing does not provide any operational or financial performance data, making it difficult to assess the company's current health.
• The disclosure is a routine filing and does not inherently signal positive or negative company performance.

Risks

• Potential for future changes in ownership by Atlas Venture entities could impact stock price volatility.
• The filing does not detail the specific investment strategy or rationale behind the ownership, leaving room for speculation.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that venture capital firms like Atlas Venture are active investors in the biotechnology and therapeutics sector. Their filings often indicate strategic investments in companies with promising research and development pipelines.

Stakeholder Impact

• Shareholders: The increased visibility of a significant institutional investor may attract further interest or signal confidence, potentially influencing share price.
• Management: The disclosure confirms a substantial investment, which may align the interests of the reporting persons with the company's strategic goals.

Next Steps

• Continued monitoring of Atlas Venture's holdings and any subsequent filings related to Obsidian Therapeutics, Inc.

Key Dates

Keywords

Obsidian Therapeutics, Atlas Venture, Schedule 13G, Beneficial Ownership, Venture Capital, Investment, Common Stock, SEC Filing